Adjuvant Stereotactic Radiosurgery With or Without Postresection Fractionated Radiation Therapy for the Management of Clival Chordomas in Adults: An International Multicenter Case Series

Bin-Alamer, Othman; Pikis, Stylianos; Mantziaris, Georgios; Abdulbaki, Arif; Mallela, Arka N.; Lu, Victor M.; Peker, Selçuk; Samancı, Yavuz; Nabeel, Ahmed M; Reda, Wael A; Tawadros, Sameh R; El-Shehaby, Amr M N; Abdelkarim, Khaled; Eldin, Reem M Emad; Sheehan, Darrah; Sheehan, Kimball; Chytka, Tomáš; Tripathi, Manjul; Madan, Renu; Speckter, Herwin; Hernández, Wenceslao; Barnett, Gene H.; Hori, Yusuke S.; Dabhi, Nisha; Aldakhil, Salman; Mathieu, David; Kondziolka, Douglas; Bernstein, Kenneth; Wei, Zhishuo; Niranjan, Ajay; Kersh, C.R.; Lunsford, L. Dade; Sheehan, Jason P.; Abou‐Al‐Shaar, Hussam

doi:10.1227/neu.0000000000002488

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many retrospective studies on clival chordoma have been published, but few have provided data on timing of recurrence based on different EORs with or without radiation therapy. 5,7,[16][17][18][19] To counsel patients and plan management, it is useful to have this more modern information.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of primary clival chordomas: a single-center retrospective study with an emphasis on the timing of recurrences based on the primary treatment

Hong,

Shinya,

Mahajan

et al. 2024

Neurosurgical Focus

View full text Add to dashboard Cite

OBJECTIVE This study aimed to provide data on extended outcomes in primary clival chordomas, focusing on progression-free survival (PFS) and overall survival (OS). METHODS A retrospective single-center analysis was conducted on patients with clival chordoma treated between 1987 and 2022 using surgery, stereotactic radiosurgery, or proton radiation therapy (PRT). RESULTS The study included 100 patients (median age 44 years, 51% male). Surgery was performed using the endoscopic endonasal approach in 71 patients (71%). Gross-total resection (GTR) or near-total resection (NTR) was attained in 39 patients (39%). Postoperatively, new cranial nerve deficits occurred in 7%, CSF leak in 4%, and meningitis in none of the patients. Radiation therapy was performed in 79 patients (79%), with PRT in 50 patients (50%) as the primary treatment. During the median follow-up period of 73 (interquartile range [IQR] 38–132) months, 41 recurrences (41%) and 31 deaths (31%) were confirmed. Patients with GTR/NTR had a median PFS of 41 (IQR 24–70) months. Patients with subtotal resection or biopsy had a median PFS of 38 (IQR 16–97) months. The median PFS of patients who received radiation therapy was 43 (IQR 26–86) months, while that of patients who did not receive radiation therapy was 18 (IQR 5–62) months. The Kaplan-Meier method showed that patients with GTR/NTR (p = 0.007) and those who received radiation therapy (p < 0.001) had longer PFS than their counterparts. The PFS rates following primary treatment at 5, 10, 15, and 20 years were 51%, 25%, 17%, and 7%, respectively. The OS rates at the same intervals were 84%, 60%, 42%, and 34%, respectively. Multivariate Cox regression analysis showed that age < 44 years (p = 0.02), greater extent of resection (EOR; p = 0.03), and radiation therapy (p < 0.001) were associated with lower recurrence rates. Another multivariate analysis showed that age < 44 years (p = 0.01), greater EOR (p = 0.04), and freedom from recurrence (p = 0.02) were associated with lower mortality rates. Regarding pathology data, brachyury was positive in 98%, pan-cytokeratin in 93%, epithelial membrane antigen in 85%, and S100 in 74%. No immunohistochemical markers were associated with recurrence. CONCLUSIONS In this study, younger age, maximal safe resection, and radiation therapy were important factors for longer PFS in patients with primary clival chordomas. Preventing recurrences played a crucial role in achieving longer OS.

show abstract